

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Motoharu SEIKI

Group Art Unit: 1642

Appln. No. : 10/551,780

(National Stage of PCT/JP2004/004876)

Examiner: Mark HALVORSON

I.A. Filed : April 2, 2004

For : LIPID MEMBRANE STRUCTURE CONTAINING ANTI-MT-MMP
MONOCLONAL ANTIBODY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Further to the previously filed Information Disclosure Statement on May 4, 2007, and pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following additional information.


1. Hatakeyama H et al.; "Tumor targeting of doxorubicin by anti-MT 1-MIVIP antibody-modified PEG liposomes." Int. J. Pharm. 342(1-2): 194-200 (2007). Epub 2007 May 10.
2. Atobe K et al.; "In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP)." Biol. Pharm. Bull. 30(5): 972-8 (2007).
3. Abstracts of the 20th annual meeting of the Academy of Pharmaceutical Science and Technology, Japan (2005), Kobayashi H et al., "Study on formulation of anti-MT1-MMP antibody-bound liposome-Optimization of binding amount of antibody-" accompanied by an English Translation.

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that this Supplemental Information Disclosure Statement is being filed in even date with a Request for Continued Examination so that a fee should not be necessary. However, Applicants hereby authorize the charging of any required fee necessary for consideration of this Supplemental Information Disclosure Statement and any of the documents cited therein to Deposit Account No. 19-0089.

If there should be any questions, the Examiner is respectfully invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Motoharu SEKI


Bruce H. Bernstein
Reg. No. 29,027

Arnold Turk
Reg. No. 33094

June 24, 2010
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191